CALR mutations occur in 20–35% of patients with ET or PMF and are associated with more pronounced thrombocytosis, younger age, fewer thromboembolic events, and an overall more favorable prognosis compared to JAK2 V617F mutant patients [35]. Here, JAK2 is linked to essential thrombocythemia.